Search company, investor...
Viridian Therapeutics company logo

Viridian Therapeutics

viridiantherapeutics.com

Founded Year

2007

Stage

Loan | IPO

Total Raised

$120.13M

About Viridian Therapeutics

Viridian Therapeutics (NASDAQ: VRDN), formerly miRagen Therapeutics, is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies. Viridian is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications.

Headquarters Location

6200 Lookout Road Suite 100

Boulder, Colorado, 80301,

United States

720.643.5200

Missing: Viridian Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Viridian Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Viridian Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Viridian Therapeutics is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Viridian Therapeutics Patents

Viridian Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Diseases of the eye and adnexa
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/13/2017

7/2/2019

MicroRNA, Molecular biology, RNA, Transcription factors, Biotechnology

Grant

Application Date

9/13/2017

Grant Date

7/2/2019

Title

Related Topics

MicroRNA, Molecular biology, RNA, Transcription factors, Biotechnology

Status

Grant

Latest Viridian Therapeutics News

Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference

Nov 28, 2022

10:30 a.m. ET The live webcast of the fireside chat will be accessible under "Events and Presentations” within “News and Events” on the Investors section of the Viridian website at viridiantherapeutics.com . A replay of the webcast will be available on the Company’s website after the event. About Viridian Therapeutics Viridian Therapeutics  is a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and incorporates half-life extension technology. VRDN-003 is an extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003 are designed for administration as convenient, low-volume, subcutaneous injections. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Viridian is based in Waltham, Massachusetts. Investor and Media Contact:

Viridian Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Viridian Therapeutics Rank

Viridian Therapeutics Frequently Asked Questions (FAQ)

  • When was Viridian Therapeutics founded?

    Viridian Therapeutics was founded in 2007.

  • Where is Viridian Therapeutics's headquarters?

    Viridian Therapeutics's headquarters is located at 6200 Lookout Road, Boulder.

  • What is Viridian Therapeutics's latest funding round?

    Viridian Therapeutics's latest funding round is Loan.

  • How much did Viridian Therapeutics raise?

    Viridian Therapeutics raised a total of $120.13M.

  • Who are the investors of Viridian Therapeutics?

    Investors of Viridian Therapeutics include Paycheck Protection Program, Signal Genetics, Atlas Venture, Boulder Ventures, Remeditex Ventures and 10 more.

  • Who are Viridian Therapeutics's competitors?

    Competitors of Viridian Therapeutics include Asuragen, Kereos, Regulus Therapeutics, Synageva BioPharma, Cerenis Therapeutics and 9 more.

Compare Viridian Therapeutics to Competitors

M
Marval Biosciences

Marval Biosciences is an early stage company, developing contrast agents for use in X-ray and Computed Tomography (CT) Imaging. Marval's lead candidate, NCTX, targets cardiovascular imaging.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

A
Ansata Therapeutics

Founded in early 2002 by Avalon Ventures and Domain Associates, Ansata Therapeutics is developing & commercializing novel medicines that capitalize on the Company's industry- leading expertise and intellectual property in molecular transduction. Ansata has several preclinical programs under development in the oncology and neurodegenerative disease areas. The company strives to rapidly advance lead compounds from late-stage preclinical research into clinical development by leveraging its proprietary knowledge of common dermatological diseases.

A
Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

A
Ascent Therapeutics

Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.

C
Corimmun

focused on the development of therapeutics for the treatment of congestive heart failure and atherosclerosis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.